Comparative

Human disease

adrenoleukodystrophy

MONDO:0018544

Mondo defines it as: “A peroxisomal disorder resulting in cerebral demyelination, axonal dysfunction in the spinal cord leading to spastic paraplegia, adrenal insufficiency and in some cases testicular insufficiency.”

1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.

Animal diseases

By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.

OMIA group Name Found by Species The chain reached Score
2955 Adrenoleukodystrophy, ABCD1-related OMIA's OMIM numbers 1 Human disease 30.0

Human genes

Each human gene of these disease groups that Open Targets links to this disease.

Open Targets links none of these groups' human genes to this disease.

Drugs tested for this disease

Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.

Drug Acts on Latest stage for this disease
Elivaldogene Autotemcel None of these genes Approved
Elivaldogene Tavalentivec None of these genes Phase 3
Albumin Human None of these genes Phase 2/3
Alemtuzumab None of these genes Phase 2
Clofarabine None of these genes Phase 2
Glyceryl Trierucate None of these genes Phase 2
Glyceryl Trioleate None of these genes Phase 2
Hydroxyurea None of these genes Phase 2
Leriglitazone None of these genes Phase 2
Melphalan None of these genes Phase 2
Mycophenolate Mofetil None of these genes Phase 2
Pioglitazone None of these genes Phase 2
Sobetirome None of these genes Phase 1
Vk-0214 None of these genes Phase 1
Bezafibrate None of these genes Unknown
Interferon Beta None of these genes Unknown
Thalidomide None of these genes Unknown

The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.